COL18A1 and neoplasm: Similarly, the adeno-associated-mediated delivery of P125A- COL18A1, a mutated endostatin gene, led to the inhibition of tumour growth and blood vessel formation [33], while the administration of Kringle 5 (K5) of human plasminogen, a potent angiogenesis inhibitor, by means of a recombinant AAV vector led to the inhibition of VEGF and tumour angiogenesis [34].